Investor Overview

Corporate Profile

Investor Highlights

Corporate Profile

Read Now
Corporate Profile

Investor Presentation

Read Now


Our Pipeline

Learn More
  • Price
  • Change

  • Copyright West LLC.
    Minimum 15 minutes delayed.
Recent Releases

Recent Releases

August 8, 2019

BeiGene Reports Second Quarter 2019 Financial Results

July 7, 2019

Priority Review Granted to BeiGene’s Supplemental New Drug Application in China for Tislelizumab in Urothelial Carcinoma

June 28, 2019

BeiGene Granted Approval to Transition from the Biotech Chapter of the Hong Kong Stock Exchange to a General Listing

Key Metrics

Key Metrics

  • 2,700


  • 1,000+

    Clinical team

  • 4


This website uses cookies to improve your overall experience. With your continued use, you are agreeing to accept our use of cookies.